About ENDRA Life Sciences Inc.
https://www.endrainc.comENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound.
CEO
Alexander Y. Tokman
Compensation Summary
(Year 2023)
Salary $387,859
Option Awards $258,341
All Other Compensation $587
Total Compensation $646,787
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public June 30, 2017
Method of going public IPO
Full time employees 21
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-07 | Reverse | 1:35 |
| 2024-08-20 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 54.46%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $3.48 M
52w High $11.96
52w Low $2.90
P/E 0.23
Volume 2.42K
Outstanding Shares 752.63K
About ENDRA Life Sciences Inc.
https://www.endrainc.comENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.33M ▲ | $-1.6M ▼ | 0% | $-2.1 ▼ | $-1.56M ▼ |
| Q2-2025 | $0 | $1.27M ▼ | $-1.23M ▼ | 0% | $-1.71 ▲ | $-1.19M ▼ |
| Q1-2025 | $0 | $1.42M ▼ | $-1.04M ▲ | 0% | $-1.86 ▲ | $-990.75K ▲ |
| Q4-2024 | $0 | $4.25M ▲ | $-4.15M ▼ | 0% | $-7.73 ▼ | $-4.1M ▼ |
| Q3-2024 | $0 | $1.51M | $-2.35M | 0% | $-2.1 | $-1.46M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $794.04K ▼ | $1.96M ▼ | $1.79M ▲ | $171.38K ▼ |
| Q2-2025 | $1.81M ▼ | $2.81M ▼ | $1.33M ▼ | $1.47M ▼ |
| Q1-2025 | $2.06M ▼ | $3.17M ▼ | $1.42M ▼ | $1.75M ▼ |
| Q4-2024 | $3.23M ▼ | $4.45M ▼ | $1.89M ▲ | $2.56M ▼ |
| Q3-2024 | $4.75M | $8.38M | $1.77M | $6.6M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.6M ▼ | $-1.16M ▼ | $0 | $149.47K ▼ | $-1.01M ▼ | $-1.16M ▼ |
| Q2-2025 | $-1.23M ▼ | $-1.11M ▲ | $0 ▲ | $857.41K ▲ | $-256.3K ▲ | $-1.11M ▲ |
| Q1-2025 | $-1.04M ▲ | $-1.29M ▲ | $-17.28K ▼ | $145.8K ▲ | $-1.16M ▲ | $-1.31M ▲ |
| Q4-2024 | $-4.15M ▼ | $-1.52M ▲ | $0 | $0 ▼ | $-1.52M ▲ | $-1.52M ▲ |
| Q3-2024 | $-2.35M | $-1.66M | $0 | $1.68K | $-1.66M | $-1.66M |
CEO
Alexander Y. Tokman
Compensation Summary
(Year 2023)
Salary $387,859
Option Awards $258,341
All Other Compensation $587
Total Compensation $646,787
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public June 30, 2017
Method of going public IPO
Full time employees 21
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-07 | Reverse | 1:35 |
| 2024-08-20 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 54.46%
Total Number Of Holders 1
Showing Top 1 of 1